SG11201906579UA - Pyridine derivative as ask1 inhibitor and preparation method and use thereof - Google Patents

Pyridine derivative as ask1 inhibitor and preparation method and use thereof

Info

Publication number
SG11201906579UA
SG11201906579UA SG11201906579UA SG11201906579UA SG11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA
Authority
SG
Singapore
Prior art keywords
preparation
pyridine derivative
ask1 inhibitor
ask1
disclosed
Prior art date
Application number
SG11201906579UA
Other languages
English (en)
Inventor
Chengde Wu
Tao Yu
Ning Li
Shuhui Chen
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of SG11201906579UA publication Critical patent/SG11201906579UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201906579UA 2017-01-22 2018-01-22 Pyridine derivative as ask1 inhibitor and preparation method and use thereof SG11201906579UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710054224 2017-01-22
PCT/CN2018/073640 WO2018133866A1 (zh) 2017-01-22 2018-01-22 作为ask1抑制剂的吡啶衍生物及其制备方法和应用

Publications (1)

Publication Number Publication Date
SG11201906579UA true SG11201906579UA (en) 2019-08-27

Family

ID=62907792

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906579UA SG11201906579UA (en) 2017-01-22 2018-01-22 Pyridine derivative as ask1 inhibitor and preparation method and use thereof

Country Status (18)

Country Link
US (1) US11040968B2 (ja)
EP (1) EP3572412B1 (ja)
JP (1) JP6650552B2 (ja)
KR (1) KR102089234B1 (ja)
CN (1) CN109071538B (ja)
AU (1) AU2018209574B2 (ja)
BR (1) BR112019014756B1 (ja)
CA (1) CA3050346C (ja)
DK (1) DK3572412T3 (ja)
EA (1) EA037005B1 (ja)
ES (1) ES2870524T3 (ja)
MX (1) MX2019008698A (ja)
MY (1) MY174821A (ja)
PH (1) PH12019501688A1 (ja)
PL (1) PL3572412T3 (ja)
SG (1) SG11201906579UA (ja)
WO (1) WO2018133866A1 (ja)
ZA (1) ZA201904737B (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190126322A (ko) * 2017-03-03 2019-11-11 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 아미드 유도체 억제제 및 그의 제조 방법 및 적용
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
KR102629267B1 (ko) 2017-05-12 2024-01-25 이난타 파마슈티칼스, 인코포레이티드 아폽토시스 신호 조절 키나아제 １ 억제제 및 이의 사용 방법
WO2018218044A2 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218051A1 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10253018B2 (en) 2017-05-25 2019-04-09 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019034096A1 (en) * 2017-08-17 2019-02-21 Sunshine Lake Pharma Co., Ltd. FUSED BICYCLIC COMPOUNDS AND THEIR USES IN MEDICINE
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN111801314B (zh) 2018-01-02 2023-10-31 西尔洛克治疗公司 Ask1抑制剂化合物及其用途
EP3787621A4 (en) 2018-05-02 2022-01-12 Enanta Pharmaceuticals, Inc. APOPTOSIS SIGNAL REGULATING KINASE 1 INHIBITORS CONTAINING TETRAZOLES AND METHODS OF USE THEREOF
US10683289B2 (en) 2018-05-02 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN112638912B (zh) * 2018-07-20 2022-04-26 福建广生中霖生物科技有限公司 作为ask1抑制剂的晶型及其制备方法和应用
WO2020030107A1 (zh) * 2018-08-10 2020-02-13 江苏豪森药业集团有限公司 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
CN111132984A (zh) * 2018-08-14 2020-05-08 江苏豪森药业集团有限公司 凋亡信号调节激酶1抑制剂的盐及其晶型
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN110922407B (zh) * 2018-09-19 2021-11-12 广东东阳光药业有限公司 苯甲酰氨基吡啶衍生物的晶型及其用途
US11345699B2 (en) 2018-11-19 2022-05-31 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US20220098171A1 (en) * 2019-01-24 2022-03-31 Jiangsu Aosaikang Pharmaceutical Co., Ltd. 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
CN110577537B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577541B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577539B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577535B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577534B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577536B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577533B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577538B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577540B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491606B (zh) * 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
UY34573A (es) * 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
AP2016009248A0 (en) * 2013-12-20 2016-05-31 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors

Also Published As

Publication number Publication date
AU2018209574B2 (en) 2021-04-08
EA201991693A1 (ru) 2019-12-30
AU2018209574A1 (en) 2019-09-05
EP3572412A1 (en) 2019-11-27
JP6650552B2 (ja) 2020-02-19
MX2019008698A (es) 2019-09-18
EA037005B1 (ru) 2021-01-26
ZA201904737B (en) 2020-05-27
EP3572412B1 (en) 2021-03-03
CA3050346A1 (en) 2018-07-26
JP2020504166A (ja) 2020-02-06
CN109071538A (zh) 2018-12-21
BR112019014756A2 (pt) 2020-03-03
PL3572412T3 (pl) 2021-09-27
KR20190110103A (ko) 2019-09-27
EP3572412A4 (en) 2019-11-27
DK3572412T3 (da) 2021-05-25
CN109071538B (zh) 2020-03-17
KR102089234B1 (ko) 2020-05-15
ES2870524T3 (es) 2021-10-27
CA3050346C (en) 2020-07-14
US20200031823A1 (en) 2020-01-30
US11040968B2 (en) 2021-06-22
PH12019501688A1 (en) 2020-03-09
MY174821A (en) 2020-05-18
WO2018133866A1 (zh) 2018-07-26
BR112019014756B1 (pt) 2021-08-10

Similar Documents

Publication Publication Date Title
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
PH12018550120A1 (en) Steroid derivative fxr agonist
MX2023001876A (es) Derivados de rapamicina.
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
MX2017013797A (es) Inhibidor de janus quinasa.
PH12019500480A1 (en) Pyridine compound
PH12018500360A1 (en) Heteroaryl derivatives as parp inhibitors
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
CR20200116A (es) Compuestos de bisamida que activan el sarcómero y sus usos
PH12019501955A1 (en) Tri-cycle compound and applications thereof
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
PH12016502246B1 (en) Carboxamide derivatives
MX2021007247A (es) Derivados de rapamicina.
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
MX2017000208A (es) Derivados de quinolizinona como inhibidores de pi3k.
PH12019550154A1 (en) Azetidine derivative
PH12020550649A1 (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
PH12021550572A1 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof